The event will be webcasted live on
atai Life Sciences’ R&D Day agenda will include:
- atai Life Sciences R&D Strategy and Pipeline Overview –
Florian Brand , Co-Founder and CEO - Fireside Chat
- Topic: The Clinical and Regulatory Landscape in Depression
- Moderator: Dr.
Heather Berlin , Neuroscientist, Clinical Psychologist, Associate Clinical Professor of Psychiatry and Neuroscience at theIcahn School of Medicine at Mount Sinai - Participating KOLs:
Gerard Sanacora , MD, PhD, Professor of Psychiatry atYale School of Medicine , Director of Yale’sDepression Research Clinic , and Co-Director of Yale’s Interventional Psychiatry ServiceHeddie Martynowicz , PhD, Regulatory professional with 30 years of neuroscience drug development experience at Janssen, Merck and BMS; President ofNeokee Pharma Consulting, LLC
- Program Updates:
Srinivas Rao , MD, PhD, Co-Founder and Chief Scientific Officer;Rolando Gutierrez-Esteinou , MD, Chief Medical Officer; andGlenn Short , PhD, Senior Vice President ofEarly Development - PCN-101 – Context and discussion of upcoming results of Phase 2a clinical trial of R-ketamine for TRD
- COMP360 – Overview Phase 3 pivotal program design of psilocybin therapy for TRD
- VLS-01 – Overview of Phase 1 trial of a buccal thin film formulation of N,N-dimethyltryptamine (DMT) for TRD in combination with atai’s digital therapeutic app IDEA-1
- RL-007 – Preview of design of the upcoming Phase 2b trial of RL-007 for cognitive impairment associated with schizophrenia
- GRX-917 – Review of preliminary pharmacokinetic and quantitative electroencephalogram (qEEG) results from Phase 1 clinical trial of deuterated etifoxine for generalized anxiety disorder
- KUR-101 – Review of positive initial results from the single ascending dose component of Phase 1 trial of oral formulation of deuterated mitragynine for opioid use disorder
About
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Forward-Looking Statements
This presentation, oral or written, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any expressed or implied statements contained in the presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the
Contact Information
Investor Contact:
Chief Financial Officer
Email: IR@atai.life
Media Contact:
Senior Director of External Affairs
Email: PR@atai.life
Source:
2022 GlobeNewswire, Inc., source